Announcements
- Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
- Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
- Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
- Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
- Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 12.90 |
Average volume | -- |
---|---|
Shares outstanding | 36.68m |
Free float | 33.31m |
P/E (TTM) | -- |
Market cap | 223.40m CHF |
EPS (TTM) | -1.78 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019 14:59 BST.
More ▼